专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005074604A2 METHODS OF DETECTING Lp-PLA2 ACTIVITY 审中-公开
标题翻译：检测Lp-PLA2活性的方法
公开(公告)号：WO2005074604A2
公开(公告)日：2005-08-18
申请号：PCT/US2005/003211
申请日：2005-02-03
申请人： DIADEXUS, INC. , WOLFERT, Robert, L. , KIM, Nam , DUAN, Xiaozhu
发明人： WOLFERT, Robert, L. , KIM, Nam , DUAN, Xiaozhu
IPC分类号： C07D271/08 , C07K16/00 , C12Q1/44 , G01N33/53 , G01N33/573
CPC分类号： C12Q1/44 , C07D271/08 , G01N2333/918 , G01N2800/32
摘要： This invention relates to a method for measuring enzymatically active Lipoproteinassociated Phospholipase A2 (Lp-PLA2) in a sample. Further, this invention relates to a Hybrid Immunocapture method for measuring enzymatically active Lp-PLA2 in a sample. Specifically, this invention relates to a Hybrid Immunocapture method for measuring enzymatically active Lp-PLA2 in a sample utilizing an enzymatically active Lp-PLA2 standard. In addition, this invention relates to a kit for measuring enzymatically active LpPLA2 in a sample. Specifically, this invention relates to a kit for measuring enzymatically active Lp-PLA2 in a sample containing an enzymatically active Lp-PLA2 standard.
摘要翻译：本发明涉及用于测量样品中的酶活性脂蛋白和害羞相关磷脂酶A2（Lp-PLA2）的方法。此外，本发明涉及用于测量样品中的酶活性Lp-PLA2的混合免疫捕获方法。具体而言，本发明涉及使用酶活性Lp-PLA2标准物测量样品中酶促活性Lp-PLA2的混合免疫捕获方法。另外，本发明涉及用于测量样品中酶促活性的Lp＆shy; PLA2的试剂盒。具体而言，本发明涉及用于测量含有酶活性Lp-PLA2标准品的样品中的酶活性Lp-PLA2的试剂盒。

2. 发明授权

EP1718967B1 METHODS OF DETECTING Lp-PLA2 ACTIVITY 有权
标题翻译：检测方法的LP-PLA2活性的影响
公开(公告)号：EP1718967B1
公开(公告)日：2013-04-24
申请号：EP05712595.7
申请日：2005-02-03
申请人： Diadexus, Inc.
发明人： WOLFERT, Robert, L. , KIM, Nam , DUAN, Xiaozhu
IPC分类号： G01N33/53 , G01N33/573 , C07K16/00
CPC分类号： C12Q1/44 , C07D271/08 , G01N2333/918 , G01N2800/32

3. 发明公开

EP1718967A2 METHODS OF DETECTING Lp-PLA2 ACTIVITY 有权
标题翻译：检测方法的LP-PLA2活性的影响
公开(公告)号：EP1718967A2
公开(公告)日：2006-11-08
申请号：EP05712595.7
申请日：2005-02-03
申请人： Diadexus, Inc.
发明人： WOLFERT, Robert, L. , KIM, Nam , DUAN, Xiaozhu
IPC分类号： G01N33/53 , G01N33/573 , C07K16/00
CPC分类号： C12Q1/44 , C07D271/08 , G01N2333/918 , G01N2800/32
摘要： This invention relates to a method for measuring enzymatically active Lipoproteinassociated Phospholipase A2 (Lp-PLA2) in a sample. Further, this invention relates to a Hybrid Immunocapture method for measuring enzymatically active Lp-PLA2 in a sample. Specifically, this invention relates to a Hybrid Immunocapture method for measuring enzymatically active Lp-PLA2 in a sample utilizing an enzymatically active Lp-PLA2 standard. In addition, this invention relates to a kit for measuring enzymatically active LpPLA2 in a sample. Specifically, this invention relates to a kit for measuring enzymatically active Lp-PLA2 in a sample containing an enzymatically active Lp-PLA2 standard.

4. 发明申请

WO2007076465A3 CLN248 ANTIBODY COMPOSITIONS AND METHODS OF USE 审中-公开
公开(公告)号：WO2007076465A3
公开(公告)日：2007-07-05
申请号：PCT/US2006/062535
申请日：2006-12-22
申请人： DIADEXUS, INC. , FAN, Rong , KIM, Nam , WOLFERT, Robert, L.
发明人： FAN, Rong , KIM, Nam , WOLFERT, Robert, L.
IPC分类号： C07K16/00
摘要： Isolated anti-Cln248 antibodies that bind to Cln248 and cells that produce the anti- Cln248 antibodies are provided. Also provided are compositions of an anti-Cln248 antibody and a carrier. In addition, isolated nucleic acids encoding an anti-Cln248 antibody, as well as an expression vector for the isolated nucleic acids are provided. Methods for identifying anti-Cln248 antibodies, methods for producing the anti-Cln248 antibodies, as well as methods for their use in killing a Cln248-expressing cancer cells and alleviating or treating a Cln248 -expressing cancer in a mammal are also provided.

5. 发明申请

WO2005021709A2 C1N101 ANTIBODY COMPOSITIONS AND METHODS OF USE ALONE AND IN COMBINATION WITH PROSTATE SPECIFIC ANTIGEN AND OTHER CANCER MARKERS 审中-公开
标题翻译： C1N101抗体组合物和使用方法，与前列腺特异性抗原和其他癌症标记物组合使用
公开(公告)号：WO2005021709A2
公开(公告)日：2005-03-10
申请号：PCT/US2004/016969
申请日：2004-06-01
申请人： DIADEXUS, INC. , DUAN, Xiaozhu , KIM, Nam , WOLFERT, Robert, L.
发明人： DUAN, Xiaozhu , KIM, Nam , WOLFERT, Robert, L.
IPC分类号： C12N
CPC分类号： G01N33/57434 , C07K16/3069 , G01N33/57449
摘要： This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Clnl01 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Clnl01 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (C1nl0l) antibodies that bind to Clnl0l in vivo. The invention also encompasses compositions comprising an anti-C1nl0l antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-C1nl0l antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-C1nl0l antibodies. The invention encompasses a method of producing the anti-C1nl0I antibodies. Other aspects of the invention are a method of killing an Clnl0l -expressing cancer cell, comprising contacting the cancer cell with an anti-Cln101 antibody and a method of alleviating or treating an Cln101 -expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Cln101 antibody to the mammal.
摘要翻译：本发明涉及评估前列腺和/或卵巢癌风险的方法。具体地，在一个实施方案中，其涉及组合使用ClnI01和前列腺特异性抗原（PSA）以确定前列腺癌的风险。在一个替代实施方案中，本发明涉及单独使用Cln101或与CA125组合以确定卵巢癌的风险。本发明进一步提供在体内结合Cln10的分离的抗前列腺或卵巢癌抗原（C1n10I）抗体。本发明还包括包含抗C1n10抗体和载体的组合物。这些组合物可以在制品或试剂盒中提供。本发明的另一方面是编码抗C1n10抗体的分离的核酸，以及包含分离的核酸的表达载体。还提供产生抗C1n10I抗体的细胞。本发明包括产生抗C1n10I抗体的方法。本发明的其它方面是杀死表达Cln10的癌细胞的方法，包括使癌细胞与抗Cln101抗体接触，以及减轻或治疗哺乳动物中表达Cln101的癌症的方法，包括给予治疗有效量的抗-Cln101抗体。

6. 发明申请

WO2004089184A2 NEW USES OF Lp-PLA2 IN COMBINATION TO ASSESS CORONARY RISK 审中-公开
标题翻译： Lp-PLA2在组合中的新用途，用于评估冠心病风险
公开(公告)号：WO2004089184A2
公开(公告)日：2004-10-21
申请号：PCT/US2004/010039
申请日：2004-04-01
申请人： DIADEXUS, INC. , WOLFERT, Robert, L. , MAGUIRE, Yu, Ping , LI, Yu, Ping , SARNO, Mark, Joseph
发明人： WOLFERT, Robert, L. , MAGUIRE, Yu, Ping , LI, Yu, Ping , SARNO, Mark, Joseph
IPC分类号： A61B
CPC分类号： G01N33/6893 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/404 , A61K31/4418 , C12Q1/44 , G01N33/92 , G01N2333/4737 , G01N2333/918 , G01N2800/32 , G01N2800/324
摘要： This invention relates to a method for assessing risk of Coronary Vascular Disease (CVD). Specifically, it relates to utilizing risk assessment from both Lipoprotein Associated Phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) in combination. In addition the invention relates to a method for assessing risk of Coronary Vascular Disease (CVD) in a patient with low to normal Low Density Lipoprotein Cholesterol (LDL) levels utilizing both LDL and Lipoprotein Associated Phospholipase A2 (Lp-PLA2). Moreover, the invention relates to the use of risk associated with Lp-PLA2, CRP and LDL in combination and specific ranges thereof to predict Coronary Vascular Disease.
摘要翻译：本发明涉及一种评估冠状动脉血管病（CVD）风险的方法。具体来说，它涉及利用脂蛋白相关磷脂酶A2（Lp-PLA2）和C反应蛋白（CRP）两者的组合利用风险评估。此外，本发明涉及一种利用低密度脂蛋白和脂蛋白相关磷脂酶A2（Lp-PLA2）在低至正常低密度脂蛋白胆固醇（LDL）水平的患者中评估冠状动脉血管疾病（CVD）风险的方法。此外，本发明涉及与Lp-PLA2，CRP和LDL相关的风险的组合及其特定范围用于预测冠状动脉血管疾病的用途。

7. 发明申请

WO2005095454A1 LNG105 ANTIBODY COMPOSITION AND METHODS OF USE, AND USE OF LNG105 TO ASSESS LUNG CANCER RISK 审中-公开
标题翻译： LNG105抗体组合物和使用方法，以及LNG105用于评估肺癌风险
公开(公告)号：WO2005095454A1
公开(公告)日：2005-10-13
申请号：PCT/US2005/010085
申请日：2005-03-25
申请人： DIADEXUS, INC. , FAN, Rong , KIM, Nam , WOLFERT, Robert, L. , PILKINGTON, Glenn
发明人： FAN, Rong , KIM, Nam , WOLFERT, Robert, L. , PILKINGTON, Glenn
IPC分类号： C07K16/00
CPC分类号： G01N33/57415 , C07K16/3023 , C07K2317/73 , G01N33/57423
摘要： This invention relates to a method for assessing risk of lung and/or breast cancer. Specifically, in one embodiment it relates to utilizing Lng105 to determine the risk of lung cancer. Specific antibodies are disclosed.
摘要翻译：本发明涉及一种评估肺癌和/或乳腺癌风险的方法。具体地，在一个实施方案中，它涉及利用Lng105来确定肺癌的风险。公开了特异性抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式